Sanyou Biopharmaceuticals
PrivateLast Round
Series C
Nov 9, 2026
Total Funding Raised
$20.78M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Sanyou Biopharmaceuticals operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series C round in November 2026.
Sanyou Biopharmaceuticals is a biotechnology company that provides contract research, development, and manufacturing organization (CRDMO) services for innovative biologic and antibody drugs.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Clinical Trials, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sanyou Biopharmaceuticals Comparables
Compare Sanyou Biopharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| FairJourney Biologics | 84% | |
| Fusion Antibodies PLC | 83% | |
| BigHat Biosciences | 83% |
For institutional investors. Book with your work email.
Sanyou Biopharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Nov 9, 2026 | ||||
| Series B Extension | Aug 2, 2022 | ||||
| Series B | Jun 26, 2021 | ||||
| Series A | May 16, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Sanyou Biopharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| 清科产投 | Series C |
| Huatai Zijin Investment | Series B Extension |
| Grand Mount Capital | Series B |
| Linghang Ventures | Series B Extension, Series B |
| Huatai Zijin Investment | Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 9, 2026
$15M round led by 清科产投
- Aug 22, 2026
Monthly visitors grew 720% MoM, from 35 to 287.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingNov 9, 2026
Sanyou Biopharmaceuticals Co. receives $15M in Series C financing exclusively from Zero2IPO Industry Investment on Nov 9th '26 in China.
- is_developingSep 24, 2026
On Sep 24th '26 in China, Sanyou Biopharmaceuticals Co. and NovoCodex formally enter a strategic collaboration to jointly develop Dual-Payload ADCs, combining AI-powered antibody and molecule libraries with site-specific conjugation technology to advance innovative ADC therapeutics.
- launchesAug 28, 2026
Sanyou Biopharmaceuticals Co. officially launches Clicklinks, an AI-STAL and SAI-DA-powered collaborative network supporting original drug discovery and preclinical development, in China on Aug 28th '26.
For institutional investors. Book with your work email.
Sanyou Biopharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Sanyou Biopharmaceuticals's valuation, stock price, and market status.
Is Sanyou Biopharmaceuticals a public or private company?
Sanyou Biopharmaceuticals is a private company.
What is the current stock price of Sanyou Biopharmaceuticals?
Sanyou Biopharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Sanyou Biopharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Sanyou Biopharmaceuticals worth (valuation)?
Valuation information for Sanyou Biopharmaceuticals is not publicly available.
Can I buy Sanyou Biopharmaceuticals stock?
Sanyou Biopharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Sanyou Biopharmaceuticals's last funding round?
Sanyou Biopharmaceuticals's most recent funding round was Series C on November 9, 2026.
Who are the main investors in Sanyou Biopharmaceuticals?
Key investors in Sanyou Biopharmaceuticals include 清科产投, Huatai Zijin Investment, Linghang Ventures, Huatai Zijin Investment.
Will Sanyou Biopharmaceuticals IPO soon?
No public IPO plans have been announced for Sanyou Biopharmaceuticals.
How can I track Sanyou Biopharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Sanyou Biopharmaceuticals's shares on secondary markets.